NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Foghorn Therapeutics Inc. FHTX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$30.9M
▲ 36.8% vs FY2024
EPS · FY25
$-1.18
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-240.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 30.9M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 240 cents on every revenue dollar this year.
Per share
USD -1.18
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-279.5%
Net margin-240.3%
Return on assets-30.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+135.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+17.1%
+135.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+54.0%
Change, 10 years—
The share count grew 54% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 198.1M
total assets, end of FY2025
Total assetsUSD 198.1M
EquityUSD -108.5M
CashUSD 80.9M
Current ratio2.73×
Equity funds -55% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
·
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−1.18
−1.58
−2.34
−2.62
−2.73
−6.23
−12.20
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
−224.5
−83.4
−236.5
·
Shares out B
0.06
0.06
0.04
0.04
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed